Cytological Biomarkers

Cytology have been act as a main tools utilised in the diagnosis of cancer. These techniques have evolved from an era of diagnosis based on haematoxylin and eosin (H&E) stained slides  to the current regular evaluation of tumours by immunocytochemistry (IHC) to confirm tumour histogenesis and subtype. In breast cancer, this means the routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors) as well as evaluation of HER2 expression  and Ki67 (a marker of tumour proliferation). These factors strongly influence prognosis and the selection of anti-cancer treatments.

 

  • cytological carcinoma
  • Cytopathology marker

Related Conference of Cytological Biomarkers

April 28-29, 2025

35th Experts Meet On Cancer Research & Therapy

Paris, France
May 26-27, 2025

15th World Congress on Breast Cancer

Rome, Italy
June 16-17, 2025

26th World Congress on Cancer Summit

Amsterdam, Netherlands
July 14-15, 2025

5th World Congress on Breast Cancer

Berlin, Germany
July 28-29, 2025

45th Euro Congress on Cancer Science & Therapy

Paris, France
August 18-19, 2025

6th Cancer Diagnostics & Treatment Conference

Rome, Italy
October 13-14, 2025

8th International Conference on Anti-Cancer Drugs & Therapies

Aix-en-Provence, France
October 20-21, 2025

21st International Conference on Cancer Research

Barcelona, Spain
November 24-25, 2025

43rd World Cancer Conference

Barcelona, Spain

Cytological Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in